So it is not reasonable to make clinical decisions based on PSA alone, a strategy that will frequently detect clinically insignificant PCa and miss clinically significant prostate cancers (csPCa, Gleason score ≥7) (7). This evidence concerns the gene KLK3 and prostate cancer.